Author(s):
Yara M Aboulmagd, Doaa Elsegaie, Menna M Hassan, Asmaa M Elbakry, Alaa A Zaky, Youssef A Elsherif
Email(s):
yara.mohamed@hu.edu.eg , doaa.mohamed@hu.edu.eg , Menna.mahmoud@hu.edu.eg , asmaa.mohamed@hu.edu.eg , alaa.zaky@eur.edu.eg , youssef.elsherif@hu.edu.eg
DOI:
10.52711/0974-360X.2026.00373 
Address:
Yara M Aboulmagd1, Doaa Elsegaie3, Menna M Hassan1, Asmaa M Elbakry2,3, Alaa A Zaky4, Youssef A Elsherif3
1Department of Pharmacology and Toxicology, Faculty of Pharmacy, Heliopolis University, Cairo, Egypt.
2Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Al-Azhar University (Girls), Cairo, Egypt.
3Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Heliopolis University, Cairo, Egypt.
4Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Egyptian Russian University, Badr City, Egypt.
*Corresponding Author
Published In:
Volume - 19,
Issue - 6,
Year - 2026
ABSTRACT:
Skin cancer is one of the most commonly diagnosed cancers globally. Although melanoma is the deadliest form of skin cancer, non-melanoma skin cancers also contribute significantly to patients’ morbidity. Yet, current skin cancer treatments often have limitations, which raises an urgency to repurpose existing medications and utilize the most advanced new drug delivery systems, like nanotechnology, to boost effectiveness, reduce side effects, and break down barriers in cancer treatment. Clotrimazole is an antimycotic drug that has been used for years to treat fungal skin infections; moreover, recent studies have highlighted its potential benefits for skin cancer. However, its nanosuspension gel formulation for skin cancer has not been investigated. This study is the first to assess a nanosuspension gel containing clotrimazole for skin cancer in comparison to the commercially available clotrimazole cream, Candistan®. Soybean lecithin was used as a nano-based drug carrier within a Carbopol gel. The physicochemical properties of the nanocarrier and the gel were assessed and optimized. The optimized formulation was then tested in the skin cancer rat model. The results demonstrated a significant improvement in both histopathological and biochemical analyses compared to those of the commercial clotrimazole product. The clotrimazole nanosuspension gel effectively reduced skin inflammation and cell proliferation in rats, significantly lowering the levels of VEGF, NF-?B-p65, KI-67, and Sox 2. These findings provide strong evidence for the potential of clotrimazole nanosuspension gel as an effective innovative treatment for skin cancer due to its anti-inflammatory and anti-proliferative properties and improved bioavailability.
Cite this article:
Yara M Aboulmagd, Doaa Elsegaie, Menna M Hassan, Asmaa M Elbakry, Alaa A Zaky, Youssef A Elsherif. Unlocking the Promise of Repurposed Clotrimazole for Skin Cancer Therapy Utilizing Nanosuspension - A Promising Anticancer Gel. Research Journal Pharmacy and Technology. 2026;19(6):2605-3. doi: 10.52711/0974-360X.2026.00373
Cite(Electronic):
Yara M Aboulmagd, Doaa Elsegaie, Menna M Hassan, Asmaa M Elbakry, Alaa A Zaky, Youssef A Elsherif. Unlocking the Promise of Repurposed Clotrimazole for Skin Cancer Therapy Utilizing Nanosuspension - A Promising Anticancer Gel. Research Journal Pharmacy and Technology. 2026;19(6):2605-3. doi: 10.52711/0974-360X.2026.00373 Available on: https://rjptonline.org/AbstractView.aspx?PID=2026-19-6-30
8. REFERENCE:
1. Saha D, Tamrakar A, Jana M, Mandal S. Skin Cancer: Dance of Death. Asian J Pharm Res. 2011; 1(2): 34-36.
2. Apalla Z, Nashan D, Weller RB, Castellsagué X. Skin Cancer: Epidemiology, Disease Burden, Pathophysiology, Diagnosis, and Therapeutic Approaches. Dermatol Ther (Heidelb). 2017; 7(1): 5-19. doi:10.1007/s13555-016-0165-y
3. Kulkarni RR, Phadtare DG, Saudagar RB. A novel approach towards nanosuspension. Asian J Pharm Res. 2015; 5(4): 186-194.
4. Abdin N, Sahu BP, Rahman SS. A Review on Formulation and Evaluation of Nanoniosomal Topical gel of Paclitaxel for skin cancer. Res J Pharm Technol. 2022; 15(6): 2849-2854.
5. Aldeeb MME, Wilar G, Suhandi C, Elamin KM, Wathoni N. Nanosuspension-based drug delivery systems for topical applications. Int J Nanomedicine. 2024: 825-844. doi:https://doi.org/10.2147/IJN.S447429
6. Crowley PD, Gallagher HC. Clotrimazole as a pharmaceutical: Past, present and future. J Appl Microbiol. 2014; 117(3): 611-617. doi:10.1111/jam.12554
7. Pienaar ED, Young T, Holmes H. Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children. Cochrane Database Syst Rev. Published online 2010. doi:10.1002/14651858.cd003940.pub3
8. Kadavakollu S, Stailey C, Kunapareddy CS and WS. Clotrimazole as a Cancer Drug: A Short Review. Physiol Behav. 2017; 176(3): 139-148. doi:10.4172/2161-0444.1000219.Clotrimazole
9. Mueller, Bruffaerts, R., Mortier, Ph., Kiekens, G., Auerbach, R. P., Cuijpers, P., Demyttenaere, K., Green, J. G., Nock, M. K., Kessler RC. Aldolase mRNA expression in endometrial cancer and the role of clotrimazole in endometrial cancer cell viability and morphology. Physiol Behav. 2016; 176(3): 139-148. doi:10.1111/j.1365-2559.2011.03944.x.Aldolase
10. Penso J, Beitner R. Detachment of glycolytic enzymes from cytoskeleton of Lewis lung carcinoma and colon adenocarcinoma cells induced by clotrimazole and its correlation to cell viability and morphology. Mol Genet Metab. 2002; 76(3): 181-188. doi:10.1016/S1096-7192(02)00046-X
11. Furtado CM, Marcondes MC, Sola-Penna M, de Souza MLS, Zancan P. Clotrimazole preferentially inhibits human breast cancer cell proliferation, viability and glycolysis. PLoS One. 2012; 7(2): 1-10. doi:10.1371/journal.pone.0030462
12. Gonçalves P, Gregório I, Araújo JR, Martel F. The effect of clotrimazole on energy substrate uptake and carcinogenesis in intestinal epithelial cells. Anticancer Drugs. 2012; 23(2): 220-229. doi:10.1097/CAD.0b013e32834d9ad2
13. Granchi C, Minutolo F. Anticancer Agents That Counteract Tumor Glycolysis. ChemMedChem. 2012; 7(8): 1318-1350. doi:10.1002/cmdc.201200176
14. Magrì A, Reina S, De Pinto V. VDAC1 as pharmacological target in cancer and neurodegeneration: Focus on its role in apoptosis. Front Chem. 2018; 6(APR): 1-17. doi:10.3389/fchem.2018.00108
15. Hirlekar SDS, Bhairy S, Bhairy S, Hirlekar R, Hirlekar R. Preparation And Characterization of Oral Nanosuspension Loaded With Curcumin. Int J Pharm Pharm Sci. 2018; 10(6): 90. doi:10.22159/ijpps.2018v10i6.22027
16. Taneja S, Shilpi S, Khatri K. Formulation and optimization of efavirenz nanosuspensions using the precipitation-ultrasonication technique for solubility enhancement. Artif Cells, Nanomedicine Biotechnol. 2016; 44(3): 978-984. doi:10.3109/21691401.2015.1008505
17. Sailaja AK, Begum N. Formulation and evaluation of cox-2 inhibitor (etoricoxib) loaded ethyl cellulose nanoparticles for topical drug delivery. Nano Biomed Eng. 2018; 10(1): 1-9. doi:10.5101/nbe.v10i1.p1-9
18. Archana S, Bhavani G. Spectrophotometric Determination and Validation of Clotrimazole in Pharmaceutical Formulations. J Pharm Med Chem. 2024; 10(2): 0-4. doi:http://dx.doi.org/10.21088/jpmc.2395.6615.10224.3
19. Gardouh A, Abou-Taleb H, Solyman S. Preparation, Characterization and Evaluation of Antifungal Activity of Clotrimazole Nanostructured Lipid Carriers. Int J Pharm Sci Res. 2019; 10(12): 5362. doi:10.13040/IJPSR.0975-8232.10(12).5362-69
20. Ibrahim ESA, Ismail S, Fetih G, Shaaban O, Hassanein K, Abdellah NH. Development and characterization of thermosensitive pluronic-based metronidazole in situ gelling formulations for vaginal application. Acta Pharm. 2012; 62(1): 59-70. doi:10.2478/v10007-012-0009-y
21. Venkatachalam S, Harsha M, Pooja M, Paranjothy M, Kumar R. Enhanced Bio-Adhesion and Sustained Delivery of Clotrimazole Encapsulated Solid Lipid Nanoparticles Loaded in Hyaluronic Acid Gel as Anti- Fungal Therapy. Br J Pharm Res. 2017; 17(1): 1-12. doi:10.9734/bjpr/2017/34063
22. Kumar R, Barathidasan R, Kumar P. Induction of skin tumour using DMBA in wistar Rat and histopathological evaluation. Indian J Vet Pathol. 2011; 16(January): 2-6.
23. Omar S, Ismail A, Hassanin K, Hamdy S. Formulation and Evaluation of Cubosomes as Skin Retentive System for Topical Delivery of Clotrimazole. J Adv Pharm Res. 2019; 3(2): 68-82. doi:10.21608/aprh.2019.9839.1079
24. Inoue J, Fujiwara K, Hamamoto H, Kobayashi K, Inazawa J. Improving the Efficacy of EGFR Inhibitors by Topical Treatment of Cutaneous Squamous Cell Carcinoma with miR-634 Ointment. Mol Ther Oncolytics. 2020; 19(December): 294-307. doi:10.1016/j.omto.2020.10.009
25. Bancroft JD. Histochemical Techniques. Butterworth-Heinemann; 2013.
26. Almukainzi M, El-Masry TA, Negm WA, et al. Gentiopicroside PLGA Nanospheres: Fabrication, in vitro Characterization, Antimicrobial Action, and in vivo Effect for Enhancing Wound Healing in Diabetic Rats. Int J Nanomedicine. 2022; 17: 1203-1225. doi:10.2147/IJN.S358606
27. Yadav AR, Mohite SK. Cancer-A silent killer: An overview. Asian J Pharm Res. 2020; 10(3): 213-216.
28. Mehri M, Karazhian M, Nikyar A, et al. Incidence Rates and Time Trends of Skin Cancer in Golestan Province, Northeastern Iran, 2005-2018. Arch Iran Med. 2024; 27(6): 289-297. doi:10.34172/aim.28801
29. Khandbahale S V. A review-Nanosuspension technology in drug delivery system. Asian J Pharm Res. 2019; 9(2): 130-138.
30. Singh N, Sondhi S, Sharma S, et al. Treatment of skin cancer by topical drug delivery of nanoparticles: a review. Res J Pharm Technol. 2021; 14(10): 5589-5598.
31. Ahmad W, Khan T, Basit I, Imran J. A comprehensive review on targeted drug delivery system. Asian J Pharm Res. 2022; 12(4): 335-340.
32. Patidar V, Sharma D, Maliwal D, Chatap V. Penetration Enhancement Techniques for Transdermal Drug Delivery System. Res J Pharm Technol. 2009; 2(1): 28-33.
33. CHEN X ting, Wang T. Preparation and characterization of atrazine-loaded biodegradable PLGA nanospheres. J Integr Agric. 2019; 18(5): 1035-1041. doi:10.1016/S2095-3119(19)62613-4
34. Tiwari R, Tiwari G, Wal P, Wal A, Maurya P. Development, characterization and transdermal delivery of dapsone and an antibiotic entrapped in ethanolic liposomal gel for the treatment of lapromatous leprosy. Open Nanomed J. 2018; 5(1). doi:10.2174/1875933501805010001
35. Kesharwani P, Gupta U. Nanotechnology-Based Targeted Drug Delivery Systems for Brain Tumors. Academic Press; 2018.
36. Kalimuthu S, Yadav A V. Nanobased Drug Delivery System : A Review. Res J Pharm Technol. 2009; 2(1): 21-27.
37. Kumar R, Jha AK, Jain SK. Nanomedicine : An Nanotechnology Emerging Area of. Res J Pharma Dos Forms Tech. 2009; 1(1): 18-21.
38. Keservani RK, Prakash Gautam S. Formulation and evaluation of baclofen liposome vesicles using lecithin. Ars Pharm. 2020; 61(3): 1-6. doi:http://dx.doi.org/10.30827/ars.v61i3.15279
39. Xia L, Tan S, Zhou Y, et al. Role of the NFκB-signaling pathway in cancer. Onco Targets Ther. 2018; 11: 2063-2073. doi:10.2147/OTT.S161109
40. Carmeliet P. VEGF as a Key Mediator of Angiogenesis in Cancer. Oncology. 2005; 69(Suppl. 3):4-10. doi:10.1159/000088478
41. Liao HF, Chen YY, Liu JJ, et al. Inhibitory Effect of Caffeic Acid Phenethyl Ester on Angiogenesis, Tumor Invasion, and Metastasis. J Agric Food Chem. 2003; 51(27): 7907-7912. doi:10.1021/jf034729d
42. Chen C, Xu ZQ, Zong YP, et al. CXCL5 induces tumor angiogenesis via enhancing the expression of FOXD1 mediated by the AKT/NF-κB pathway in colorectal cancer. Cell Death Dis. 2019; 10(3). doi:10.1038/s41419-019-1431-6
43. Menon SS, Guruvayoorappan C, Sakthivel KM, Rasmi RR. Ki-67 protein as a tumour proliferation marker. Clin Chim Acta. 2019; 491(November 2018): 39-45. doi:10.1016/j.cca.2019.01.011
44. Riehn M, Klopocki E, Molkentin M, Reinhardt R, Burmeister T. A BACH2-BCL2L1 Fusion Gene Resulting from a Lymphoma Cell Line BLUE-1. Cancer. 2011; 396(January): 389-396. doi:10.1002/gcc
45. Hussenet T, Manoir S Du. SOX2 in squamous cell carcinoma: Amplifying a pleiotropic oncogene along carcinogenesis. Cell Cycle. 2010; 9(8): 1480-1486. doi:10.4161/cc.9.8.11203
46. Wang H, Zhou Y, Liu Q, Xu J, Ma Y. Prognostic value of SOX2, cyclin D1, P53, and ki-67 in patients with esophageal squamous cell carcinoma. Onco Targets Ther. 2018; 11: 5171-5181. doi:10.2147/OTT.S160066.